drug_type
RELEVANT_DRUG
intervention_type
Cellular gene therapy (TCR-engineered autologous T cells)
drug_description
Autologous peripheral blood T cells engineered with the Sleeping Beauty transposon/transposase to express patient-specific TCRs recognizing mutated neoantigens; adoptive cellular gene therapy mediating HLA-restricted tumor cell killing.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_category
ENGINEERED TCR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous peripheral blood T cells are genetically modified using the Sleeping Beauty transposon/transposase system to express patient-specific TCRs that recognize mutated neoantigen peptides presented by HLA on tumor cells. Upon infusion, TCR–HLA engagement activates the T cells to mediate targeted, HLA-restricted tumor cell killing via cytotoxic effector mechanisms (perforin/granzyme) and cytokine release.
drug_name
Sleeping Beauty Transposed PBL
nct_id_drug_ref
NCT04102436